Company analysis

Emerging Pharma
Big Pharma
Mid Pharma
Japan Pharma
Hot Topics
M&A Analysis

Text search

Sort by Popularity (sales)

Display 15 Products per page

JP Morgan Healthcare Conference Preview

$3,000.00

PharmaVitae previews companies presenting at the JP Morgan Healthcare Conference to be held in San Francisco over 8–11 January 2018.
January 10, 2018
Find out more
Company Analysis: Johnson & Johnson

$3,000.00

PharmaVitae explores Johnson & Johnson’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Shire Company Analysis

$3,000.00

PharmaVitae explores Shire’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
August 30, 2018
Find out more
Company Analysis: Shionogi

$3,000.00

PharmaVitae explores Shionogi’s prescription pharmaceutical performance and outlook through to 2029.
January 29, 2021
Find out more
Regenerative Medicine Landscape

$2,995.00

The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies.
July 21, 2017
Find out more
2016 M&A Analysis

$3,000.00

Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how

they may influence the market and future deal-making.
September 7, 2016
Find out more
Big Pharma Licensing Trends, 2011–15

$5,000.00

Between 2011 and 2015, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and sales valued at $10bn or more – signed over 1,100 drug-focused deals, growing at a compound annual growth rate of 10%.
October 14, 2016
Find out more
Company Analysis: Takeda

$3,000.00

PharmaVitae explores Takeda’s prescription pharmaceutical performance and outlook over 2019–29.
January 29, 2021
Find out more
Company Analysis: Otsuka

$3,000.00

PharmaVitae explores Otsuka’s prescription pharmaceutical performance and outlook over 2019–29.
January 29, 2020
Find out more
Company Analysis: Eisai

$3,000.00

PharmaVitae explores Eisai’s prescription pharmaceutical performance and outlook over 2019–29.
January 28, 2021
Find out more
Company Analysis: Sumitomo Dainippon

$3,000.00

PharmaVitae explores Sumitomo Dainippon’s prescription pharmaceutical performance and outlook over 2019–29.
January 28, 2021
Find out more
Company Analysis: Daiichi Sankyo

$3,000.00

PharmaVitae explores Daiichi Sankyo’s prescription pharmaceutical performance and outlook over 2019–29.
January 28, 2021
Find out more
Company Analysis: Astellas

$3,000.00

PharmaVitae explores Astellas’s prescription pharmaceutical performance and outlook over 2019–29.
January 28, 2021
Find out more
Japan Pharma Outlook

$3,000.00

Datamonitor’s Japan Pharma peer set contains the top 10 companies headquartered in Japan: Takeda Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Dainippon Sumitomo, Shionogi & Co and Kyowa Hakko Kirin.
September 28, 2016
Find out more
Company Analysis: Teva

$3,000.00

PharmaVitae explores Teva’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *